ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma (Q38337608)

2 September 2017

title

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma (English)

1 reference

2 September 2017

8

1 reference

2 September 2017

6

Axel Le Cesne

0 references

Roberta Sanfilippo

Roberta Sanfilippo

5

0 references

Paolo Giovanni Casali

Paolo Casali

4

0 references

Jacques Robert

Jacques Robert

15

0 references

Isabelle Ray-Coquard

9

Isabelle Ray-Coquard

1 reference

2 September 2017

11

Jean-Michel Coindre

1 reference

2 September 2017

7

Ian Judson

1 reference

2 September 2017

13

Juan-Carlos Tercero

1 reference

2 September 2017

Antoine Italiano

1

1 reference

2 September 2017

Armelle Laurand

2

1 reference

2 September 2017

Audrey Laroche

3

1 reference

2 September 2017

Binh Bui

10

1 reference

2 September 2017

Antonio Nieto

12

1 reference

2 September 2017

Jose Jimeno

14

1 reference

2 September 2017

Philippe Pourquier

16

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

2 September 2017

1 reference

2 September 2017

volume

117

1 reference

2 September 2017

issue

15

1 reference

2 September 2017

page(s)

3445-3456

1 reference

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

DNA Damage, Aging, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Unique features of the mode of action of ET-743.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Tuberin haploinsufficiency is associated with the loss of OGG1 in rat kidney tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

BRCA1 and its toolbox for the maintenance of genome integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Predicting drug response and toxicity based on gene polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Retracted: A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Improved survival in women with BRCA-associated ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

Molecular Detection of the Synovial Sarcoma Translocation t(X;18) by Real-Time Polymerase Chain Reaction in Paraffin-Embedded Material

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

inferred from DOI database lookup

7 January 2021

based on heuristic

Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25925

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.25925

1 reference

2 September 2017

1 reference